<DOC>
	<DOC>NCT01813812</DOC>
	<brief_summary>This is a multicenter, double-blinded, double-dummy, active-controlled, randomized, Phase III clinical trial to evaluate the efficacy and safety of DA-6034 and to demonstrate the non-inferiority of DA-6034 compared with Rebamipide in patients with acute or chronic gastritis. Subjects will receive 45mg, 90mg of DA-6034 and 300mg of Rebamipide, two tablets, three times a day for two weeks.</brief_summary>
	<brief_title>A Study to Evaluate the Efficacy and Safety of DA-6034 and to Demonstrate the Non-inferiority of DA-6034</brief_title>
	<detailed_description />
	<mesh_term>Gastritis</mesh_term>
	<mesh_term>Gastritis, Atrophic</mesh_term>
	<mesh_term>Rebamipide</mesh_term>
	<criteria>Diagnosed with acute gastritis or chronic gastritis 1 or more erosions found in the gastroscope examination Age should be: 20≤age≤75 A patient with peptic ulcer and a gastroesophageal reflux disease. Received a medication including nonsteroid antiinflammatory drug 2 weeks before the initiation Had a surgery regarding gastroesophageal A patient with ZollingerEllison syndrome Had a medical history of a malignant tumor A patient who is currently taking antithrombotic drugs</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>March 2013</verification_date>
</DOC>